Oddo BHF raises target for Novo-Nordisk stock to DKK 305

Published on 10/22/2026 at 10:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Oddo BHF lifted its target from DKK 221 to DKK 305 on October 20, 2026. Novo-Nordisk stock costs EUR 35.07 on October 22, 2026, with CagriSema weight loss at 25.00 percent.

Targets and clinical evidence

Oddo BHF lifted its Novo Nordisk target to DKK 305 on October 20, 2026.
CagriSema was associated with 25.00 percent weight loss at week 68 in 2,309 women.
Novo-Nordisk stock trades at EUR 35.07 at 10:00 a.m. CEST at Lang & Schwarz on October 22, 2026.
Novo Nordisk is scheduled to publish its third-quarter results on November 3, 2026.

Kopenhagener Hafen mit Brücken, Aquarell in Pastelltönen, nordische Atmosphäre — Novo Nordisk A/S (DK0062498333): Kopenhagener Hafenpanorama mit historischen Brücken in weichen Aquarell-Pastelltönen gemalt, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) saw Oddo BHF raise its price target from DKK 221 to DKK 305 on October 20, 2026, according to MarketScreener. The move kept Oddo BHF's neutral recommendation in place. On the same date, Novo Nordisk reported new CagriSema data in women, with an average weight loss of 25.00 percent at week 68 versus 3.00 percent for placebo, according to PR Newswire.

Target reflects a cautious stance

The DKK 305 target is 37.99 percent above the old DKK 221 target, calculated from the two figures reported by MarketScreener. Oddo BHF nevertheless retained a neutral view, so the higher valuation marker does not amount to a positive rating change. MarketScreener also listed a DKK 298.07 average target and 26 analysts in its consensus table.

Three dated clinical milestones

The company had reported adjusted second-quarter sales of DKK 78.488 billion and adjusted operating profit growth of 11.00 percent on August 4, 2026, according to Via Ritzau. On September 21, 2026, Novo Nordisk reported CagriSema weight loss of 12.40 percent versus 9.10 percent for tirzepatide in REIMAGINE 5, also through Via Ritzau. The October 20, 2026 analysis added the 25.00 percent result in 2,309 women and compared it with 3.00 percent for placebo, according to PR Newswire.

What does 25 percent mean?

The result is hypothesis generating because the analysis was conducted after the main trial, and the 25.00 percent figure used an efficacy estimate assuming participants stayed on treatment. The release also reported adverse-event discontinuation of 5.90 percent with CagriSema versus 3.50 percent with placebo, giving investors a counterweight to the headline efficacy number.

Next reporting date matters

Novo Nordisk is scheduled to publish its third-quarter results on November 3, 2026, according to MarketScreener. That report will provide the next operating-period test for the company after its second-quarter adjusted sales growth of 7.00 percent at constant exchange rates.

Stock price and company profile

Novo-Nordisk stock was trading at EUR 35.07 at Lang & Schwarz on October 22, 2026 at 10:00 a.m. CEST. The quote gives the market a current euro reference while the clinical data and the November reporting date provide the more durable investor context. Novo Nordisk is a Danish pharmaceutical company focused on diabetes, obesity and rare diseases.